Stevens Capital Management LP Sells 4,132 Shares of Humana Inc. (NYSE:HUM)

Stevens Capital Management LP cut its holdings in shares of Humana Inc. (NYSE:HUM) by 60.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,733 shares of the insurance provider’s stock after selling 4,132 shares during the period. Stevens Capital Management LP’s holdings in Humana were worth $1,251,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HUM. Mariner LLC increased its position in shares of Humana by 2.3% during the 3rd quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock valued at $6,869,000 after purchasing an additional 312 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Humana by 27.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider’s stock worth $13,595,000 after acquiring an additional 6,034 shares during the last quarter. Silverarc Capital Management LLC bought a new stake in shares of Humana during the 3rd quarter valued at $4,865,000. Vest Financial LLC increased its stake in shares of Humana by 43.3% in the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock worth $12,815,000 after purchasing an additional 8,455 shares in the last quarter. Finally, Artemis Investment Management LLP raised its holdings in Humana by 9.6% in the 4th quarter. Artemis Investment Management LLP now owns 64,573 shares of the insurance provider’s stock worth $29,563,000 after purchasing an additional 5,672 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock traded down $5.51 on Friday, hitting $305.90. The company had a trading volume of 1,212,671 shares, compared to its average volume of 1,994,928. The firm has a market cap of $36.91 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21. The company has a 50-day moving average price of $328.56 and a 200-day moving average price of $395.71. The company has a quick ratio of 1.59, a current ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the previous year, the company posted $9.38 earnings per share. Humana’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, equities research analysts predict that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is currently 22.04%.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HUM shares. TheStreet lowered shares of Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Royal Bank of Canada dropped their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research note on Thursday. Cantor Fitzgerald decreased their target price on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research note on Thursday. Raymond James began coverage on Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. Finally, Wells Fargo & Company cut their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $433.74.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.